

## ASX Release

---

# Appendix 4C: Third Quarter FY 2021 Activities Report

**PERTH, AUSTRALIA – 27 April 2021:** SUDA Pharmaceuticals Ltd (ASX: SUD), a leader in oromucosal drug delivery, today released its Appendix 4C for the consolidated group for the third quarter of FY 2021.

### Highlights

- End of period cash balance of \$4.28m.
- Following a review of operations, the Company created efficiencies for ongoing formulation development work.
- SUDA has contracted the services of MedPharm to assist with formulation development for anagrelide, which is being developed as an adjunct therapy for metastatic disease.
- SUDA added two world renowned experts to its Scientific Advisory Board.
- Management continued to source and evaluate new technologies to strengthen the Company's pipeline.

During the quarter ended 31 March 2021, the Company was pleased with the following developments:

- SUDA has contracted the services of MedPharm, who will perform formulation development work and provide valuable expertise, assisting to stabilise and optimise the oral spray formulation for anagrelide. MedPharm is a world-leading Contract Development and Manufacturing Organisation (CDMO) that focus on topical and transdermal product design and development services and they have played a role in the development of 55 approved pharmaceutical products.
- SUDA made two important appointments to its Scientific Advisory Board; Professor Anil K. Sood, MD and Professor Gunnar Birgegård, MD, PhD.

**Professor Sood** is a Professor and Vice Chair for Translational Research in the Departments of Gynecologic Oncology and Cancer Biology and co-director of the Center for RNA Interference and Non-Coding RNA at The University of Texas MD Anderson Cancer Center. He is also Director of the multi-disciplinary Blanton-Davis Ovarian Cancer Research Program. Professor Sood co-leads the Ovarian Cancer Moon Shot Program. Pioneering studies performed by Professor Sood's research team highlighted the role that platelets play in the progression of ovarian cancer and their impact on patient survival. That research was published in the prestigious journal, the New England Journal of Medicine.

**Professor Birgegård** is a Professor of Haematology at Uppsala University, Uppsala, Sweden. He was Chairman of the Nordic Study Group for Myeloproliferative disorders and is currently involved with studies assessing platelet reduction therapy with anagrelide and interferon. He is also a member of Leukemia Network Work Package 9 on Myeloproliferative disorders. Professor Birgegård has been involved in studies analysing the clinical use of anagrelide for the treatment of Essential Thrombocythemia and other Myeloproliferative Neoplasms.

- SUDA management continued to identify and evaluate technologies that it believes align with its core areas of focus, oncology and the central nervous system. The Company continues to work on strengthening the pipeline by adding technologies that it believes best suit the Company's short- and long-term strategic objectives and will create value for shareholders.

Dr Baker commented "We see the use of anagrelide as a unique but important strategy to treat cancer patients. We look forward to progressing the formulation development for anagrelide utilising the expertise within MedPharm. In addition, we are delighted that we have received strong support from such esteemed researchers in the field of platelet biology and cancer."

In addition, he commented "We are encouraged by the new technologies that the team have uncovered and are currently under review. We will continue to diligently assess the technologies that we believe align with our focus areas and will create value for shareholders."

### **Corporate Update**

The net outflow from operating activities for the quarter was \$0.88m with a bank balance of \$4.28m as at 31 March 2021. SUDA received \$196,000 in government grants and tax incentives for the period.

*Dr Michael Baker, CEO and Managing Director of Suda Pharmaceuticals Ltd has authorised the release of this announcement to the market.*

For and on behalf of the Board and for further information please contact:

**Dr Michael Baker**

**Chief Executive Officer & Managing Director**

**SUDA Pharmaceuticals Ltd**

Tel +61 (0) 403 468 187

mbaker@sudapharma.com

#### **NOTES TO EDITORS:**

##### **About SUDA Pharmaceuticals Ltd**

SUDA Pharmaceuticals Ltd (ASX: SUD) is a drug delivery company focused on oro-mucosal administration, headquartered in Perth, Western Australia. The Company is developing low-risk oral sprays using its OroMist® technology to reformulate existing pharmaceuticals. The many potential benefits of administering drugs through the oral mucosa (i.e. cheeks, tongue, gums and palate) include ease of use, lower dosage, reduced side effects and faster response time. SUDA's product pipeline includes ZolpiMist™, a first-in-class oral spray of zolpidem tartrate for the treatment of short-term insomnia. ZolpiMist is approved by the TGA and is marketed in the USA. SUDA has rights to the product outside of the US and Canada. Other products in development include oral sprays for the treatment of migraine headache, motion sickness, drug resistant epilepsy and certain cancers.

For more information, visit [www.sudapharma.com](http://www.sudapharma.com)

## Appendix 4C

### Quarterly cash flow report for entities subject to Listing Rule 4.7B

**Name of entity**

Suda Pharmaceuticals Ltd

**ABN**

35 090 987 250

**Quarter ended ("current quarter")**

31 March 2021

<b>Consolidated statement of cash flows</b>	<b>Current quarter \$A'000</b>	<b>Year to date (9 months) \$A'000</b>
<b>1. Cash flows from operating activities</b>		
1.1 Receipts from customers	-	248
1.2 Payments for		
(a) research and development	(222)	(622)
(b) product manufacturing and operating costs	-	-
(c) advertising and marketing	-	-
(d) leased assets	(28)	(81)
(e) staff costs	(396)	(1,321)
(f) administration and corporate costs	(436)	(1,440)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	3	6
1.5 Interest and other costs of finance paid	-	-
1.6 Income taxes paid	-	-
1.7 Government grants and tax incentives	196	1,085
1.8 Other (provide details if material)	-	(568)
<b>1.9 Net cash from / (used in) operating activities</b>	<b>(883)</b>	<b>(2,693)</b>
<b>2. Cash flows from investing activities</b>		
2.1 Payments to acquire or for:		
(a) entities	-	-
(b) businesses	-	-
(c) property, plant and equipment	(54)	(125)
(d) investments	-	(2,000)
(e) intellectual property	(98)	(272)
(f) other non-current assets	-	-

For personal use only

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (9 months) \$A'000
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	2,000
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
<b>2.6</b>	<b>Net cash from / (used in) investing activities</b>	<b>(152)</b>	<b>(397)</b>
<b>3.</b>	<b>Cash flows from financing activities</b>		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	40	6,892
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	(189)	(475)
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if material)	-	-
<b>3.10</b>	<b>Net cash from / (used in) financing activities</b>	<b>(149)</b>	<b>6,417</b>
<b>4.</b>	<b>Net increase / (decrease) in cash and cash equivalents for the period</b>		
4.1	Cash and cash equivalents at beginning of period	5,469	977
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(883)	(2,693)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(152)	(397)

## Quarterly cash flow report for entities subject to Listing Rule 4.7B

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (9 months) \$A'000
4.4	Net cash from / (used in) financing activities (item 3.10 above)	(149)	6,417
4.5	Effect of movement in exchange rates on cash held	(2)	(21)
<b>4.6</b>	<b>Cash and cash equivalents at end of period</b>	<b>4,283</b>	<b>4,283</b>

5. Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts		Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	1,733	1,319
5.2	Call deposits	2,550	4,150
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
<b>5.5</b>	<b>Cash and cash equivalents at end of quarter (should equal item 4.6 above)</b>	<b>4,283</b>	<b>5,469</b>

6. Payments to related parties of the entity and their associates		Current quarter \$A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	158
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-

*Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.*

Item 6.1 Reflects amounts paid to directors including director's fees, salaries, superannuation and consulting fees.

<b>7. Financing facilities</b>	<b>Total facility amount at quarter end \$A'000</b>	<b>Amount drawn at quarter end \$A'000</b>
<i>Note: the term "facility" includes all forms of financing arrangements available to the entity.</i>		
<i>Add notes as necessary for an understanding of the sources of finance available to the entity.</i>		
7.1 Loan facilities	-	-
7.2 Credit standby arrangements	-	-
7.3 Other (please specify)	-	-
<b>7.4 Total financing facilities</b>	-	-
<b>7.5 Unused financing facilities available at quarter end</b>		-
7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.		

<b>8. Estimated cash available for future operating activities</b>	<b>\$A'000</b>
8.1 Net cash from / (used in) operating activities (item 1.9)	(883)
8.2 Cash and cash equivalents at quarter end (item 4.6)	4,283
8.3 Unused finance facilities available at quarter end (item 7.5)	-
8.4 Total available funding (item 8.2 + item 8.3)	4,283
<b>8.5 Estimated quarters of funding available (item 8.4 divided by item 8.1)</b>	4.9
<i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i>	
8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:	
8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?	
Answer: N/A	
8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?	
Answer: N/A	
8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?	
Answer: N/A	
<i>Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.</i>	

## Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: 27 April 2021

Authorised by: By the Board

## Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.